HER2 Testing Market - Regional Analysis
North American Market Insights
North America industry is expected to account for largest revenue share of 44% by 2035. Because of its high acceptance rate and greater product penetration, North America is expected to be the leading regional market for HER2 testing. A significant need for HER2 testing exists in the area as well. The United States leads the market in North America as a result of the nation's rising breast cancer incidence rate. Growing rates of cancer, including stomach, breast, and other cancers, a well-established healthcare system, and rising healthcare spending are the main factors driving the regional HER2 testing market. According to projections from the American Cancer Society, 310,720 new instances of invasive breast cancer will be identified in women in the US by 2024. There will be roughly 56,500 new diagnoses of ductal carcinoma in situ (DCIS).
APAC Market Insights
HER2 testing market in the Asia Pacific region is projected to hold the second largest revenue share of about 27% during the forecast period. In terms of the ongoing adoption of new technologies and research from businesses in the field of HER2 testing research, China and India are predicted to expand quickly. HER2 testing is in high demand in the Asia Pacific due to high occurrences of gastric and gastroesophageal junction cancer. Patients with advanced HER2-positive disease have a better quality of life owing to HER2-targeted therapy, which also makes high-quality testing methods more important to determine whether patients have responded to the treatment.
